The perils of delivering anti-malarial drugs through private sector examined

November 9, 2012 by Donna Hesterman in Medications

The perils of delivering anti-malarial drugs through private sector examined

Enlarge

This is a privately owned drug store in Madagascar. This type of facility is often used by to distribute anti-malaria drugs in sub-Saharan countries, making the drugs accessible but sometimes given to people who don’t need it. Andrew Tatem, an associate professor of geography at UF’s Emerging Pathogens Institute, helped to track this pattern. Credit: Capsule Survey Firm

(Medical Xpress)—Getting high-quality anti-malarial drugs to people in places like Zanzibar and Mozambique is a tricky business.

A 2009 program, called the Affordable Medicines Facility-, or AMFm, tried to do it by giving subsidies directly to , but critics are now saying that the program has promoted dangerous misuse of these expensive medications. A new study co-authored by a University of Florida researcher, however, suggests that misuse is a bigger problem in some areas than others, and that an AMFm-like approach could still have value in some regions.

The study is published in the Nov. 2 edition of the journal Science.

"It's a bit silly to talk about the market for anti-malarials in Africa in general terms because there is so much variation in malaria prevalence, availability of health services, finances and culture within the region," said Justin Cohen, senior technical adviser for the Clinton Health Access Initiative and lead author of the study.

A "one-size-fits-all" approach to working with the private sector in Africa will inevitably be an ill fit for some places, he said.

In many , more people have access to privately run health facilities or drug stores than to public health institutions, so using them as a means to get better quality medicines to people in outlying areas is an attractive strategy. However, the decentralized nature of the private sector has also made it difficult to assess how many drugs are being purchased and how the drugs are being used.

"Part of the problem has been that we've never had good information for how big the private sector market is for anti-malarials in sub-Saharan Africa," Cohen said.

Andrew Tatem, associate professor of geography at UF's Emerging Institute, was able to help in that regard.

Tatem combined from a project he runs called AfriPop with sub-Saharan information to estimate the number of people buying anti-malarials from private sector markets. The team then combined the results with data from the Malaria Atlas Project to see how demand for medication stacked up against known rates of malaria infection.

"We found that in some regions, as few as 5 percent of the people taking anti-malarials likely had malaria." Tatem said.

Malaria is often assumed to be the culprit when children run a fever in sub-Saharan Africa. When that happens, parents will often treat it with anti-malarials the way that Americans might treat flu symptoms with a cold medicine.

Taking the drugs when they are not needed wastes money, and it could possibly cause drug-resistant strains of malaria to develop. Cohen said that AMFm critics aren't wrong when they say that programs should be providing more diagnostic tests along with these medications. The study notes that while 655 million people purchased anti-malarial medications, only about 50 million rapid diagnostic tests were delivered globally in 2010.

However, Cohen said that increasing access to affordable drugs even in the absence of diagnosis may be a good short-term strategy in places like Nigeria where infection rates are high.

"Ultimately, everyone should receive effective diagnosis and the appropriate treatment for the true cause of their illness," Cohen said. "But in the short term, if most people in an area have malaria, we can do a lot of good by increasing accessibility to higher quality malaria drugs."

Testing everyone who needs it will be expensive and resources are currently limited. According to the study, donations for malaria control declined in 2012 for the first time in a decade.

"It's great to talk in the abstract about how things should be ideally," Cohen said. "But in the end, you have to get going and do your best with what you have."

Journal reference: Science search and more info website

Provided by University of Florida search and more info website

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Medications created 3 hours ago | popularity 5 / 5 (1) | comments 0

Global recommendations on child medicine

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

Medications created 4 hours ago | popularity not rated yet | comments 0

Analgesics prescribed more heavily to women than to men, study finds

Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...

Medications created 12 hours ago | popularity not rated yet | comments 0

Breakup of physician, drug company relationship could improve health care, cut cost

A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...

Medications created May 20, 2013 | popularity 5 / 5 (1) | comments 0

FDA has safety concerns on Merck insomnia drug

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

Medications created May 20, 2013 | popularity not rated yet | comments 0


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

Drugs found to both prevent and treat Alzheimer's disease in mice

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.